Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

NCT02302157 is registered in ClinicalTrials.gov with Lineage Cell Therapeutics, Inc. as lead sponsor.

NCT NCT02302157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02302157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury
Lead sponsor
Lineage Cell Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2015
Completion date
December 31, 2018
Enrollment
25 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cervical spinal cord injury, spinal cord trauma, spine injury